- Home
- XBIT vs NRXS Comparison
XBIT vs NRXS Comparison
Compare XBIT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XBIT | NRXS |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 78.9M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XBIT | NRXS |
|---|---|---|
| Price | $2.19 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 43.4K | ★ 63.2K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $2.09 | $2.21 |
| 52 Week High | $3.44 | $9.33 |
Technical Indicators
Market Signals| Indicator | XBIT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 35.03 |
| Support Level | $2.19 | $5.50 |
| Resistance Level | $2.46 | $7.37 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.00 | 44.07 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).